Key result
Highest NHHR tertile is linked to ~22% higher odds of lifetime cancer prevalence.
Why the study?
Is an elevated non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) associated with increased cancer prevalence in US adults?
Cross-Sectional (n=26,416)
Is an elevated non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) associated with increased cancer prevalence in US adults?
Odds Ratio: 1.22 (95% CI 1.04–1.48)
p-value: p=0.035
Elevated NHHR levels are positively associated with self-reported lifetime cancer prevalence in US adults, suggesting its potential role as a biomarker.
Lipid metabolism is recognized as a key player in carcinogenesis, but the association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and overall cancer prevalence remains unclear in the US population. This study aimed to investigate the association between NHHR and cancer prevalence based on self-reported lifetime cancer diagnoses in a nationally representative US population. We utilized data from the National Health and Nutrition Examination Survey from 2007 to 2016. The primary exposure was NHHR, and the primary outcome was self-reported lifetime cancer diagnosis. Associations were assessed using weighted multivariable logistic regression models, with NHHR modeled as both a continuous variable and tertiles. Model 1 was unadjusted; Model 2 adjusted for age, sex, race/ethnicity, education level, marital status, and family income-to-poverty ratio; and Model 3 further adjusted for total cholesterol, glycated hemoglobin, physical activity, and drinking status. The analysis included adults aged 18 years or older with available NHHR and cancer-related information. Exploratory cancer-specific analyses were performed for prostate, breast, colorectal, and lung cancers. Among 26,416 participants, 2451 (9.0%) reported a lifetime cancer diagnosis. The mean age of the participants was 49.48 ± 17.67 years, and the mean NHHR was 2.96 ± 1.48. In the fully adjusted model, each unit increase in NHHR corresponded to 7% higher odds of cancer prevalence (odds ratio: 1.07 [95% confidence interval: 1.01–1.13]). NHHR tertiles were defined as T1 (0.45–2.11), T2 (2.11–3.11), and T3 (3.11–15.03). Compared with participants in the lowest tertile, those in the highest tertile had 22% higher odds of cancer prevalence (odds ratio: 1.22 [95% confidence interval: 1.04–1.48], P = .035). Subgroup analyses suggested potential effect modification by sex. Elevated NHHR levels were positively associated with cancer prevalence in US adults, suggesting that NHHR may be a potential biomarker warranting further investigation.
No takes yet. Share an insight, caveat, or question.
Shou et al. (2026) conducted a cross-sectional in Cancer (n=26,416). Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) vs. Lowest tertile of NHHR was evaluated on Self-reported lifetime cancer diagnosis (OR 1.22, 95% CI 1.04-1.48, p=0.035). The highest tertile of NHHR was associated with 22% higher odds of lifetime cancer prevalence compared to the lowest tertile in US adults (OR 1.22; 95% CI 1.04-1.48; P=0.035).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: